Could a gut pill ease long COVID? new trial tests larazotide
NCT ID NCT05747534
First seen May 22, 2026 · Last updated Jun 22, 2026 · Updated 4 times
Summary
This Phase 2a study tests whether larazotide, a drug that tightens the gut lining, can reduce long COVID symptoms in people aged 7 to 50. Participants take the drug or a placebo four times daily for 21 days. The goal is to see if it safely improves symptoms like fatigue, brain fog, and breathing trouble.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-ACUTE COVID-19 SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Larazotide (AT1001), a drug that tightens the gut lining to reduce inflammation
What this could lead to
If it works, this could point toward a treatment for long COVID by addressing gut-related inflammation.
What could go wrong
This is an early Phase 2a trial with only 150 participants, so results may not apply to everyone. The drug is taken four times daily for 21 days, and side effects are still being studied.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.